Michael R. Bielski, J.D., M.S. is a medical device, biotech and agtech entrepreneur. As an inventor and founder, Michael has brought technologies from conception, prototyping and patenting, through product development and manufacturing, and ultimately to the generation of licensing revenue, clinical use and sales. Michael is an expert across all areas of high-technology commercialization including out-licensing and start-up company formation. Michael works closely with clinician inventors out-licensing their medical technologies to industry. A structured licensing process, built around the in-licensing due diligence requirements of medical device companies, has resulted in multiple licenses for clinician inventors. This process includes validation of clinical problems and proposed solutions, professional development of marketing materials and highly-focused outreach to industry.Michael also works closely with technology companies to build innovation programs that identify, evaluate and in-license/acquire new technologies to support their product development efforts. These new technologies may also form the basis for revenue-generating out-licensing programs.Michael is an IP strategy expert, working closely with companies of all sizes to build systems that align their patents with the technical competitive advantages of their products. Along with being responsible for managing the filing of hundreds of patents, Michael is also an inventor on 5 medical device patents and applications.Michael founded DevTech Partners to advise inventors, founders and tech transfer offices on how to more effectively commercialize their technologies. Specialties: Patent Licensing, Start-Ups, Medical Devices, Clinician Invention and Licensing, Prototyping, Engineering, Product Development, Manufacturing, Regulatory, Intellectual Property Strategy, Patent Strategy, Venture Capital, Business Planning, Technology Transfer, Business Planning, Due Diligence
Listed skills include Patents, Biotechnology, Intellectual Property, Commercialization, and 21 others.